Evidence map›Paper›PMID 30837601›Full record

ArticleScientific reports2019

Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [

Maxwell T Laws, Robin E Bonomi, Swatabdi Kamal, David J Gelovani, Jeremy Llaniguez, Shreya Potukutchi, Xin Lu, Thomas Mangner, Juri G Gelovani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Maxwell T LawsDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA.ORCID 0000-0002-6820-3846
Robin E BonomiDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
Swatabdi KamalDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
David J GelovaniDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
Jeremy LlaniguezDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
Shreya PotukutchiDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
Xin LuPositron Emission Tomography Center, Wayne State University, Detroit, MI, 48202, USA.
Thomas MangnerPositron Emission Tomography Center, Wayne State University, Detroit, MI, 48202, USA.
Juri G GelovaniDepartment of Biomedical Engineering, College of Engineering and School of Medicine, Wayne State University, Detroit, MI, 48202, USA. juri.gelovani@wayne.edu.
Wayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Novel HDAC Class III Specific Radiotracers for PET Imaging.R01DA030333 · NIDA · WAYNE STATE UNIVERSITY · PI GELOVANI, JURI GEORGE · 2010 to 2014
$3.3M
HDAC Class IIa specific PET radiotracers for PET imaging of CNSRC2DA028912 · NIDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GELOVANI, JURI GEORGE · 2009 to 2010
$3.3M
NCI NIH HHS P30 CA022453NIDA NIH HHS R01 DA030333NIDA NIH HHS RC2 DA028912
6 · The paper itself

Abstract

HDAC class IIa enzymes (HDAC4, 5, 7, 9) are important for glioma progression, invasion, responses to TMZ and radiotherapy, and prognosis. In this study, we demonstrated the efficacy of PET/CT/(MRI) with [

Indexed as

AnimalsApoptosisCell ProliferationFluorine RadioisotopesGliomaHistone Deacetylase InhibitorsHistone DeacetylasesHumansKruppel-Like Factor 4Magnetic Resonance ImagingMaleMiceMolecular ImagingPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRatsFluorine RadioisotopesHistone Deacetylase InhibitorsHistone DeacetylasesKLF4 protein, humanKlf4 protein, mouseKlf4 protein, ratKruppel-Like Factor 4Radiopharmaceuticals

Identifiers

PMID30837601
PMCPMC6401080
OpenAlexW2920558115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.